GlassScriptPhysician profile
Kimberly J Ackerman
NPI 1598437071
$13,660.60
in general payments reported to CMS, 2019-2025
59 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $3,228 · 2023: $4,830 · 2024: $3,267 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,188 · Travel and Lodging: $825 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,188.04 |
| Travel and Lodging | $824.88 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,655.93 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,528.32 | 2021-2025 | Duopa, Botox, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $754.31 | 2023-2025 | |
| Argenx US, INC. | $709.12 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Jazz Pharmaceuticals INC. | $564.63 | 2022-2024 | |
| Biogen, INC. | $548.33 | 2022-2024 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $541.57 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Lilly USA, LLC | $535.34 | 2022-2024 | Amyvid, Emgality, Reyvow |
| Alnylam Pharmaceuticals INC. | $463.92 | 2021-2024 | Onpattro |
| Amgen INC. | $373.63 | 2022-2025 | Uplizna, Aimovig |
| Harmony Biosciences LLC | $351.26 | 2022-2025 | Wakix |
| Neurocrine Biosciences, INC. | $316.08 | 2022-2025 | Ingrezza, Ongentys |
| Eisai INC. | $308.60 | 2021-2025 | |
| Horizon Therapeutics Plc | $302.18 | 2022-2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $300.72 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.